PEAK6’s Prime Medicine PRME Stock Holding History

PEAK6’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35,063	Closed	-$156K	–	3280
2025 Q3	$194K	Buy	+35,063	New	+$142K	﹤0.01%	2479
2025 Q1	–	Sell	-30,013	Closed	-$87.6K	–	3490
2024 Q4	$87.6K	Buy	+30,013	New	+$105K	﹤0.01%	2744

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

PEAK6's PRME Position: Q4 2025 in Review

PEAK6 sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 35,063 shares — an estimated $156K sold.

PEAK6 first reported a position in PRME in Q4 2024 and held it in 2 quarters. The position peaked at $194K in Q3 2025. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

PEAK6 reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
PEAK6 sold 35,063 Prime Medicine shares in Q4 2025, an estimated $156K.
PEAK6 first reported a position in Prime Medicine in Q4 2024 and held it in 2 quarters.
PEAK6's Prime Medicine position peaked at $194K in Q3 2025.
183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on PEAK6's 13F filing for Q4 2025, filed 13 Feb 2026.